Institute of Biomedicine of Seville (IBiS) at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Institute of Biomedicine of Seville (IBiS) brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on regulatory T cells given a chimeric antigen receptor, aimed at graft-versus-host disease and at alpha-synuclein in Parkinson's disease. A separate strand covers residual DNA and protein testing for lentiviral vectors made in academic GMP facilities.
| Organization | ESGCT 2026 Attendance |
|---|---|
Institute of Biomedicine of Seville (IBiS) Seville, Spain | |
Biomedical research institute on the Virgen del Rocío University Hospital campus, run jointly with the University of Seville and CSIC. | Poster Wed Oct 28 1:30pm–3:30pm Development of 4th generation CAR-Tregs for the treatment of GvHD Poster Wed Oct 28 1:30pm–3:30pm Emerging Quality Control Requirements for Lentiviral Vector Manufacturing: Implementation of Residual DNA and Protein Testing in Academic GMP Facilities Poster Thu Oct 29 2:00pm–4:00pm Antigen-Specific CAR-Treg Cell Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease Poster Thu Oct 29 2:00pm–4:00pm Bcl2 and Mcl1 overexpression enhances the persistence and antitumor fitness of CAR-T cells |
Instantly find 20 buyers from Institute of Biomedicine of Seville (IBiS)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction